EI
IMUX icon

EAM Investors’s Immunic IMUX Stock Holding History

EAM Investors’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,972
Closed -$923K – 340
2020
Q3 		$923K Buy
+4,972
New +$814K 0.22% 223

Other funds holding IMUX

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

EAM Investors's IMUX Position: Q4 2020 in Review

EAM Investors sold out of Immunic (IMUX) in Q4 2020, closing a stake of 4,972 shares — an estimated $923K sold.

EAM Investors first reported a position in IMUX in Q3 2020 and held it in 1 quarter. The position peaked at $923K in Q3 2020. 69 funds tracked by Wall St. Rank hold IMUX as of Q4 2020.

  • EAM Investors reported no remaining Immunic position as of Q4 2020 after selling out during the quarter.
  • EAM Investors sold 4,972 Immunic shares in Q4 2020, an estimated $923K.
  • EAM Investors first reported a position in Immunic in Q3 2020 and held it in 1 quarter.
  • EAM Investors's Immunic position peaked at $923K in Q3 2020.
  • 69 funds tracked by Wall St. Rank held Immunic as of Q4 2020.

Based on EAM Investors's 13F filing for Q4 2020, filed 11 Feb 2021.